PharmaShots | Incisive News in 3 Shots

Subscribe Now

moderate to severe

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

August 25, 2021

Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens

Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens

November 12, 2020

Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis

Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis

September 21, 2020

LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis

LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis

July 10, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us